As biologics boom, here’s how manufacturers are keeping up

Stevanato’s focus on biologic-related vials and delivery devices has put it in a unique position amid a quickly growing market.

By Michael Gibney • July 19, 2023

AI’s great expectations

With AI expectations riding high, here’s a look at some areas where the technology could be most useful in drug development. 

By Karissa Waddick • July 19, 2023

Explore the Trendline➔

Clinical trial diversity

As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.

By PharmaVoice staff

Threads joins the social media fray. Here’s what it means for pharma marketers.

Meta’s new platform is drawing Twitter comparisons and could hold potential for pharma marketers in patient and HCP communication.

By Karissa Waddick • July 18, 2023

DCTs create fresh privacy challenges for review boards. Now there are guidelines.

A new toolkit developed by industry stakeholders paves the way for faster reviews.

By Kelly Bilodeau • July 17, 2023

Flagship, PhRMA prioritize experience in hot summer exec changes

With major projects brewing at both organizations, these new leaders will hit the ground running. 

By Karissa Waddick • July 14, 2023

Novo’s workhorse Ozempic could shine in new areas

Besides its popularity as a weight loss drug, Ozempic and treatments like it are being investigated for Alzheimer’s, liver disease and other surprising indications.

By Michael Gibney • July 13, 2023

FDA’s upcoming psychedelic review looms large for a budding industry

A new psychedelic guidance from the agency gives a clue into how it could analyze drugs in the space, but industry leaders are eager for more.

By Karissa Waddick • July 12, 2023

Merck’s New Jersey campus is getting a biotech makeover

With a purchase of the pharma giant’s Kenilworth campus, Onyx Equities is looking to make the spot a go-to biotech hub.

By Michael Gibney • July 11, 2023

Cancer R&D is shifting — here’s what’s changing most

A report from IQVIA shows China gaining ground in cancer drug R&D, and a growing industry focus on new drug targets.

By Kelly Bilodeau • July 10, 2023

Following FDA’s full approval of Leqembi, here’s what else is in the Alzheimer’s pipeline

Leqembi’s U.S. approval is a milestone in Alzheimer’s research and medicine — and there are a few other late-stage biologic drugs that could follow.

By Michael Gibney • July 7, 2023

Pharma’s strike-from-all-sides attack on the IRA could be decided by the Supreme Court

New lawsuits challenging the Inflation Reduction Act’s price negotiation program hit the government with multiple Constitution-based challenges.

By Alexandra Pecci • July 6, 2023

A BMS exec’s journey around the world in 90 days

As BMS grapples with upcoming patent cliffs, Emma Charles, the new SVP of intercontinental markets, is focused on expanding its footprint.

By Karissa Waddick • July 5, 2023

Women’s healthcare investments are hot. So where are the new menopause drugs?

NK3 receptor antagonists offer a new option, but experts say more are needed.

By Kelly Bilodeau • July 5, 2023

The stories you’ve read the most in 2023 (so far)

From staff shortages to presidential candidates and the M&A outlook, here are our most-read stories from the first half of the year.

By PharmaVoice Staff • July 3, 2023

A pharma summer — how leaders unwind and recharge their teams in the warmer months

Vacation is calling, but so are patients. Here's how the industry adjusts in the summer. 

By Michael Gibney • June 30, 2023

Major clinical trial trends transforming life sciences research

From AI to diversity and decentralized trials, here’s how clinical trial operations are evolving.

By Karissa Waddick • June 29, 2023

Transgender patients are rarely included in clinical trials. Can pharma fix it?

Transgender and nonbinary patients suffer more adverse health outcomes than the general population, yet are often underrepresented in clinical research. Now, there’s momentum to change the status quo.

By Karissa Waddick • June 29, 2023

Pharma is still figuring out how to make DEI work. Here are some of the strategies companies are trying

Although DEI efforts have ramped up, the industry is still searching for proven ways to get results.

By Alexandra Pecci • June 28, 2023

Intercept’s NASH retreat is the latest setback for a challenging liver disease

Intercept Pharmaceuticals has stepped out of the race to the first U.S. approved treatment for the complicated liver disease NASH, leaving room for other pharmas to get their foot in the door.

By Michael Gibney • June 27, 2023

A unique study on COVID shows how machine learning can help personalize medicine

Based on real-world data from patients in China, researchers were able to pinpoint factors that led to recurring infections — and which drug combos helped.

By Kelly Bilodeau • June 26, 2023

How Sanofi is taking a ‘creative’ approach to dealmaking

Dr. Monika Vnuk, SVP of global partnering and business development, is setting her sights on out-of-the-box partnerships.

By Taren Grom • June 23, 2023

10 years proud: Pharma’s top companies for LGBTQ+ inclusivity

These six Big Pharma companies have ranked among the best places to work for LGTBQ+ equality by the Human Rights Campaign Foundation for over 10 years. Here’s why. 

By Karissa Waddick , Taren Grom • June 22, 2023

Duty to serve: an Army officer’s unexpected path to GSK

How Court Horncastle, SVP, business unit head of the anti-infective and respiratory team at GSK, applies lessons from combat to his work in antibiotics.

By Alexandra Pecci • June 21, 2023

The spotlight is on accelerated approvals — now FDA could run a tighter ship

As the fallout of the Aduhelm approval continues, scrutiny of the speedier pathway has increased and the pressure is on to close a key gap in the regulation.

By Kelly Bilodeau • June 20, 2023

AI has secured a footing in drug discovery. Where does it go from here?

The AI revolution is bringing a new era of drug discovery, and the potential for more uses is greater and faster than ever before.

By Michael Gibney • June 20, 2023